Serum microRNA-205 as a novel biomarker for cervical cancer patients

Cancer Cell International

Xiaoming Yao¹  Jiaming Zhang¹  Wanwei Yang¹  Shuxia Wang¹  Guiping Wan²  Quanhui Ma¹ 

[1] Department of clinical laboratory, Jiangsu Province hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China;Department of obstetrics and gynecology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China

关键词: Biomarker;    Prognosis;    Diagnosis;    Serum miR-205;    Cervical cancer;   

Others  :  1121669
DOI  :  10.1186/s12935-014-0081-0

 received in 2014-05-19, accepted in 2014-08-01,  发布年份 2014

【 摘 要 】

Objective

Serum microRNAs (miRNAs) are a novel class of diagnostic and prognostic biomarkers for numerous cancers. However, the level and clinical relevance of circulating miR-205 transcripts in human serum of cervical cancer patients are unclear. The purpose of this study was to determine serum miR-205 levels in cervical cancer patients and explore its association with clinicopathological factors and prognosis.

Methods

Serum miR-205 expression was investigated in 60 cervical cancer patients and 60 healthy normal controls by using real-time PCR. Correlations between miR-205 expression and the clinicopathological features and prognosis of cervical cancer patients were then evaluated. Receiver operating characteristic curves were used to evaluate the sensitivity and specificity of serum miR-205.

Results

Serum miR-205 was significantly upregulated in cervical cancer patients compared with healthy donors (p < 0.01), and a high level of miR-205 expression was correlated with poor tumor differentiation (p = 0.009), lymph node metastasis (p = 0.015) and increased tumor stage (p = 0.001). The serum miR-205 level was capable of separating advanced stage from early stage metastatic cervical cancer from non-metastatic samples and poorly differentiated tumors from differentiated tumors with an area under the curve values of 0.74, 0.694 and 0.717, respectively. The expression of miR-205 was also higher in the cervical cancer tissues compared with the para-carcinoma tissues. In addition, Kaplan-Meier survival analysis showed that cervical cancer patients with high miR-205 expression tended to have shorter overall survival. In multivariate Cox regression analysis, miR-205 was identified as an independent prognostic marker.

Conclusions

Serum miR-205, which is upregulated in cervical cancer, represents a predictive biomarker for the prognosis of cervical cancer patients.

【 授权许可】

   
2014 Ma et al.; licensee Springer

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wenzel L, Dogan-Ates A, Habbal R, Berkowitz R, Goldstein DP, Bernstein M, Kluhsman BC, Osann K, Newlands E, Seckl MJ, Hancock B, Cella D: Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr 2005, 34:94-98.
• [2]Paradkar PH, Joshi JV, Mertia PN, Agashe SV, Vaidya RA: Role of cytokines in genesis, progression and prognosis of cervical cancer. Asian Pac J Cancer Prev 2014, 15:3851-3864.
• [3]Mariuzzi G, Santinelli A, Valli M, Sisti S, Montironi R, Mariuzzi L, Alberti R, Pisani E: Cytometric evidence that cervical intraepithelial neoplasia I and II are dysplasias rather than true neoplasias. An image analysis study of factors involved in the progression of cervicallesions. Anal Quant Cytol Histol 1992, 14:137-147.
• [4]Behtash N, Mehrdad N: Cervical cancer: screening and prevention. Asian Pac J Cancer Prev 2006, 7:683-686.
• [5]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [6]Williams AE: Functional aspects of animal microRNAs. Cell Mol Life Sci 2008, 65:545-562.
• [7]Ruan K, Fang X, Ouyang G: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009, 285:116-126.
• [8]Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C: Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer. Int J Oncol 2012, 41:1897-1912.
• [9]Anindo MI, Yaqinuddin A: Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg 2012, 10:443-449.
• [10]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
• [11]Wittmann J, Jäck HM: Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 1806, 2010:200-207.
• [12]Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3:e2557.
• [13]Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO: miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One 2012, 7:e46990.
• [14]Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27:2030-2037.
• [15]Qin AY, Zhang XW, Liu L, Yu JP, Li H, Wang SZ, Ren XB, Cao S: MiR-205 in cancer: an angel or a devil? Eur J Cell Biol 2013, 92:54-60.
• [16]Moldovan L, Batte K, Wang Y, Wisler J, Piper M: Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR.Methods Mol Biol 2013, 1024:129–145.
• [17]Orang AV, Safaralizadeh R, Hosseinpour Feizi MA, Somi MH: Diagnostic and prognostic value of miR-205 in colorectal cancer. Asian Pac J Cancer Prev 2014, 15:4033-4037.
• [18]Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 2013, 8:e77853.
• [19]Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27:2030-2037.
• [20]Lukaszuk K, Liss J, Wozniak I, Sliwinski W, Emerich J, Wojcikowski C: HPV and histological status of pelvic lymph node metastases in cervical cancer: a prospective study. J Clin Pathol 2004, 57:472-476.
• [21]Zhao S, Yao D, Chen J, Ding N: Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomarkers 2013, 17:631-636.
• [22]Chen J, Yao D, Li Y, Chen H, He C, Ding N, Lu Y, Ou T, Zhao S, Li L, Long F: Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med 2013, 32:557-567.